We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Monitoring Reduces Mortality in Women at High Risk of BRCA1 Breast Cancer

By HospiMedica International staff writers
Posted on 05 Mar 2024

Women carrying pathogenic BRCA1 or BRCA2 gene mutations have a significantly high lifetime breast cancer risk, estimated at 70%. More...

While about a third of these women choose to undergo risk-reducing mastectomy, the majority prefer enhanced surveillance instead. In North America, it's advised that women with BRCA1 or BRCA2 gene mutations start annual magnetic resonance imaging (MRI) screenings from age 25 or 30 up until the age of 70. It's crucial to assess how effective MRI surveillance is in reducing mortality. However, challenges such as lead time bias and the overdetection of cancer can impact survival rates. Hence, comparing mortality among women with BRCA1 or BRCA2 mutations who undergo MRI surveillance with those who do not is vital. Now, the findings of a new study suggest that MRI surveillance among women with a BRCA1 sequence variation is associated with reduced breast cancer mortality risk.

This international study that involved researchers from the Sant Pau Research Institute (Barcelona, Spain) and included data from 2.488 women from 59 centers in 11 countries highlighted a reduction in mortality associated with early detection without the need for invasive surgical interventions. The study included 2,488 women with an average age of 41.2 at entry. Of these, 1,756 (70.6%) had at least one MRI as part of their surveillance, while 732 (29.4%) underwent no MRI tests. After an average follow-up of 9.2 years, 344 women (13.8%) developed breast cancer, with 35 (1.4%) succumbing to the disease. The results, after an average of 9.2 years of follow-up, showed a significant decrease in mortality among participants.

The study underscores the importance of non-invasive monitoring methods as a preferable approach to managing breast cancer risk in women with genetic predispositions. These findings pave the way for further research on the impact of MRI surveillance in women with BRCA2 variations and may lead to reconsiderations of prevention strategies for high-risk women. The research emphasizes the value of tailoring breast cancer prevention strategies to individual needs, favoring less invasive options where feasible.

Related Links:
Sant Pau Research Institute


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hypodermic Syringe
SurTract™ Safety Syringe
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.